BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-16 pm EDT			5-day change	1st Jan Change
86.82 ^USD	+3.05%		+7.84%	-17.74%

Jul. 15	BIONTECH : In transition
Jul. 12	European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	MT

Biontech CEO Says To Provide Additional Data In 7 Days On Efficacy Of Its Vaccine Against The UK Coronavirus Variant - J.P.Morgan Conf

January 11, 2021 at 11:54 am EST

Jan 11 (Reuters) - BioNTech SE:

* BIONTECH CEO SAYS TO PROVIDE ADDITIONAL DATA IN 7 DAYS ON EFFICACY OF ITS VACCINE AGAINST THE UK CORONAVIRUS VARIANT, AND ADDL DATA ON THE SOUTH AFRICAN VARIANT OVER THE NEXT 10 DAYS - J.P.MORGAN CONF Further company coverage:

Latest news about BioNTech SE

BIONTECH : In transition	Jul. 15
European Equities Traded in the US as American Depositary Receipts Climb Higher in Friday Trading	Jul. 12	MT
European Equities Traded in the US as American Depositary Receipts Rise Slightly in Thursday Trading	Jul. 11	MT
CureVac Notes New Court Trial Timeline for Patent Cases Against Pfizer, BioNTech	Jul. 11	MT
CureVac Provides Trial Dates for Patent Litigation Against Pfizer, BioNTech	Jul. 11	MT
RTW Biotech Opportunities Ltd Appoints Baroness Nicola Blackwood as an Independent, Non-Executive Director	Jul. 11	CI
European Equities Traded in the US as American Depositary Receipts Trend Higher in Wednesday Trading	Jul. 03	MT
Moderna, Pfizer-BioNTech COVID-19 Vaccine Patent Legal Battle Gets Mixed UK Ruling	Jul. 02	MT
Pfizer-BioNTech, Moderna Set to Appeal Mixed UK Ruling in COVID-19 Vaccine Patent Case	Jul. 02	MT
European Equities Traded in the US as American Depositary Receipts Nudge Higher in Friday Trading	Jun. 28	MT
Pfizer: CHMP recommends new Covid vaccine	Jun. 28	CF
Would you like some more inflation?	Jun. 28
Pfizer Inc. and BioNTech SE Receives Positive CHMP Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in the European Union	Jun. 28	CI
Pfizer, BioNTech Get Positive Committee Opinion for Omicron JN.1-Adapted COVID-19 Vaccine in European Union	Jun. 27	MT
Pfizer, BioNTech Get Positive CHMP Opinion for New Covid-19 Vaccine	Jun. 27	DJ
BioNTech, Duality Biologics Receive FDA Fast-Track Designation for Prostate Cancer Drug	Jun. 24	MT
BioNTech Cancer Treatment Gets US FDA Fast Track Designation	Jun. 24	DJ
US FDA Places Partial Clinical Hold on BioNTech's Cancer Drug Trial	Jun. 18	MT
Sector Update: Health Care Stocks Ease in Afternoon Trading	Jun. 17	MT
Top Midday Stories: Nvidia Gets SCOTUS Review of Crypto Sales Lawsuit; Apple Supplier Develops Material for Solid-State Batteries; OpenAI Reportedly Launches Medical AI Tool; Walt Disney's 'Inside Out 2' Sets Biggest Opening of 2024; IQVentures to Acquire Aaron's	Jun. 17	MT
Bank Stocks Help Nudge European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading	Jun. 17	MT
BioNTech Says US FDA Placed Partial Clinical Hold on Cancer Drug Trial	Jun. 17	MT
US FDA puts partial clinical hold on BioNTech's early-stage study of cancer drug	Jun. 17	RE
European Equities Traded in the US as American Depositary Receipts Trend Sharply Lower in Tuesday Trading	Jun. 11	MT
European Equities Traded in the US as American Depositary Receipts Lower in Monday Trading	Jun. 10	MT

Chart BioNTech SE

Duration

Period

More charts

Company Profile

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-08-04 - Q2 2024 Earnings Call

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BIONTECH : In transition

July 15, 2024 at 12:16 pm EDT

More Strategies

Ratings for BioNTech SE

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

79.78 EUR

Average target price

103.5 EUR

Spread / Average Target

+29.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONTECH SE	-17.74%	20.33B
VERTEX PHARMACEUTICALS INCORPORATED	+20.17%	127B
REGENERON PHARMACEUTICALS, INC.	+24.67%	117B
ARGENX SE	+25.44%	27.67B
GENMAB A/S	-15.17%	16.79B
BEIGENE, LTD.	-15.21%	15.63B
NEUROCRINE BIOSCIENCES, INC.	+11.91%	14.84B
WUXI APPTEC CO., LTD.	-47.10%	14.65B
SAREPTA THERAPEUTICS, INC.	+54.50%	14.43B
INSMED INCORPORATED	+151.63%	12.49B

Bio Therapeutic Drugs